Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing

This article was originally published in The Tan Sheet

Executive Summary

FDA will wield tight oversight of Johnson & Johnson subsidiary McNeil Consumer Healthcare's OTC manufacturing operations under a consent decree filed after the firm's quality-control changes failed to satisfy the agency.

You may also be interested in...



DoJ Aims To ‘Do Something About’ Crime In FDA-Regulated Industries

In a frank warning at a FDLI meeting, DoJ Director of Consumer Protection Michael Blume says the agency’s role is clear once it takes on a case investigated by FDA or FTC. Blume notes the dietary supplement category “has become something of an emphasis for us in the department.”

DoJ Aims To ‘Do Something About’ Crime In FDA-Regulated Industries

In a frank warning at a FDLI meeting, DoJ Director of Consumer Protection Michael Blume says the agency’s role is clear once it takes on a case investigated by FDA or FTC. Blume notes the dietary supplement category “has become something of an emphasis for us in the department.”

DoJ Aims To ‘Do Something About’ Crime In FDA-Regulated Industries

In a frank warning at a recent FDLI conference, DoJ Director of Consumer Protection Michael Blume says the agency’s role is clear once it takes on a case investigated by FDA or FTC. “We are committed to prosecuting individuals, and we’re seeing that now, more and more,” Blume said.

Related Content

Topics

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel